Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.82 |
| ▸ | POLB | P06746 | 1/20 | 0.82 |
| ▸ | GAA | P10253 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | LTA4H | P09960 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | BACE1 | P56817 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 3/20 | 0.57 |
| ▸ | HTR7 | P34969 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31475230 | 1.00 | KDM4E (0.82) | KDM4EPOLBGAAALDH1A1MEN1 | |
| SCHEMBL17687942 | 0.98 | KDM4E (0.84) | KDM4EPOLBGAAALDH1A1MEN1 | |
| SCHEMBL17177129 | 0.98 | KDM4E (0.84) | KDM4EPOLBGAAALDH1A1MEN1 | |
| SCHEMBL24862351 | 0.87 | KDM4E (0.65) | KDM4EPOLBGAAALDH1A1MEN1 | |
| SCHEMBL3657047 | 0.86 | KDM4E (0.64) | KDM4EPOLBGAAALDH1A1MEN1 | |
| SCHEMBL5237958 | 0.86 | KDM4E (0.64) | KDM4EPOLBGAAALDH1A1MEN1 | |
| SCHEMBL1640980 | 0.83 | LTA4H (0.68) | KDM4EPOLBGAALTA4HL3MBTL1 | |
| SCHEMBL4085732 | 0.81 | LTA4H (0.66) | KDM4EPOLBGAALTA4HBACE1 | |
| SCHEMBL4084094 | 0.81 | LTA4H (0.66) | KDM4EPOLBGAALTA4HBACE1 | |
| SCHEMBL18483417 | 0.81 | LTA4H (0.66) | KDM4EPOLBGAAALDH1A1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049071-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | BEYANG THERAPEUTICS CO LTD (CN) | 2026-02-19 | — | — | US | disclosed |
| EP-4556466-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | Beyang Therapeutics Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024032584-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | 苏州必扬医药科技有限公司 | 2024-02-15 | — | — | WO | disclosed |
| US-20210206762-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS (R&D) LIMITED (GB) | 2021-07-08 | — | — | US | disclosed |
| CN-106866658-B | 1H-pyrrolo [2,3-b ] pyridine derivatives and their use as kinase inhibitors | 沃纳利斯(R&D)有限公司 | 2021-04-27 | — | — | CN | disclosed |
| US-10889582-B2 | 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors | VERNALIS (R&D) LIMITED (GB) | 2021-01-12 | — | — | US | disclosed |
| CN-111484493-A | 1H-pyrrolo [2,3-b ] pyridine derivatives and their use as kinase inhibitors | 沃纳利斯(R&D)有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20200095217-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-03-26 | — | — | US | disclosed |
| US-10450288-B2 | Hydroxy formamide derivatives and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-20180362526-A1 | 1H-PYRROLO [2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS DEVELOPMENT LIMITED (GB) | 2018-12-20 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| EP-1809614-A2 | BENZOTRIAZINE INHIBITORS OF KINASES | Targegen, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2007061741-A2 | MODULATORS OF THE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061741-A2 | MODULATORS OF THE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
| WO-2006101977-A2 | PYRIMIDINE COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005096784-A2 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | KDM4E 1689/4885POLB 1540/4885GAA 3793/4885 |
| US-20200095217-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | BMP1, BMPR1A, BMPR2 | KDM4E 3090/4885POLB 2487/4885GAA 872/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | KDM4E 1689/4885POLB 1540/4885GAA 3793/4885 |
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | KDM4E 1405/4885POLB 1133/4885GAA 4136/4885 |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | SRC, CAMK4, CAMK2G | KDM4E 1214/4885POLB 4627/4885GAA 3756/4885 |
| US-10450288-B2 | Hydroxy formamide derivatives and their use | BMP1, BMPR1A, BMPR2 | KDM4E 3090/4885POLB 2487/4885GAA 872/4885 |
| US-20180362526-A1 | 1H-PYRROLO [2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MAP4K2, MAP3K1, MAP3K19 | KDM4E 727/4885POLB 1391/4885GAA 2233/4885 |
| US-20210206762-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MAP4K2, MAP3K1, MAP3K19 | KDM4E 727/4885POLB 1391/4885GAA 2233/4885 |
| US-10889582-B2 | 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors | MAP4K2, MAP3K1, MAP3K19 | KDM4E 727/4885POLB 1391/4885GAA 2233/4885 |
| US-20260049071-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | KDR, FLT1, ERBB2 | KDM4E 3216/4885POLB 3058/4885GAA 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.